Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Other Non Operating Income (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Other Non Operating Income data on record, last reported at $288000.0 in Q3 2025.

  • For Q3 2025, Other Non Operating Income rose 90.73% year-over-year to $288000.0; the TTM value through Sep 2025 reached $299000.0, down 80.67%, while the annual FY2024 figure was $506000.0, 69.95% down from the prior year.
  • Other Non Operating Income reached $288000.0 in Q3 2025 per PLX's latest filing, up from $272000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $1.8 million in Q4 2022 and bottomed at -$680000.0 in Q4 2024.
  • Average Other Non Operating Income over 5 years is $352842.1, with a median of $288000.0 recorded in 2025.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 88500.0% in 2022, then plummeted 288.37% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at -$2000.0 in 2021, then surged by 88500.0% to $1.8 million in 2022, then plummeted by 79.58% to $361000.0 in 2023, then tumbled by 288.37% to -$680000.0 in 2024, then skyrocketed by 142.35% to $288000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $288000.0 in Q3 2025, $272000.0 in Q2 2025, and $419000.0 in Q1 2025.